Cyfuse BiomedicalCyfuse Biomedical K.K.4892東証グロース医薬品FY ending Dec 2025, non-consolidated, J-GAAP

Cyfuse Biomedical FY ending Dec 2021 results

Cyfuse Biomedical brought in ¥708.2M in revenue.

Out of every ¥100 of sales, about ¥10 is left as operating profit.

Where the money goes

For every ¥100 Cyfuse Biomedical sells, how much goes where, and how much is kept.

FY ending Dec 2021

Margin funnel (derived from reported values)Gross margin 80.6% → Operating margin 10.0% → Net margin 20.2%

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第16期(2025/01/01－2025/12/31)
ID S100XV4M2026-03-27Open
EDINET (FSA Japan)
有価証券報告書－第14期(2023/01/01－2023/12/31)
ID S100T55F2024-03-27Open
EDINET (FSA Japan)
有価証券報告書－第13期(2022/01/01－2022/12/31)
ID S100QGWF2023-03-28Open

Extracted from XBRL: 34

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.